Intracardiac Thrombus in Coronavirus Disease-2019

Suganya Karikalan, Karpaga Vinayaga Institute of Medical Sciences
Munish Sharma, Baylor College of Medicine
Megha Chandna, Texas A&M University, College Station
Manju Sachdev, Texas A&M Health Science Center, College Station
Ajay Gaalla, DeTar Hospital, Victoria
Farah Yasmin, Dow University of Health Sciences
Reena Shah, Aga Khan University
Iqbal Ratnani, DeBakey Heart & Vascular Center
Salim Surani, Texas A&M University


Intracardiac thrombus is often seen as a complication of ischemic heart disease (IHD) and non-ischemia cardiomyopathies (NICM). The advancements in imaging modalities and therapeutic options have helped reduce the complications arising from ventricular thrombi, such as systemic embolization. Here we present two cases of intracardiac thrombus associated with coronavirus disease (COVID) 19, one with an apical thrombus in the left ventricle and the other with a thrombus in the right ventricle adjacent to chordae tendinae. The effects of covid-19 on the cardiovascular system are yet to be thoroughly evaluated. Venous and arterial thrombosis is commonly associated with COVID-19 but in situ detection of intracardiac thrombus has not been very frequently reported. Intracardiac thrombus and embolization pose a very high risk of complications in COVID-19.

The coronavirus pandemic caused by SARS-CoV-2 during 2019-2021 has caused several deaths and has resulted in many long-term consequences, many of which remain unclear. In-hospital complications from COVID-19 are better reported due to constant monitoring. The ongoing, late, and chronic complications arising from COVID-19 require more vigilant case-by-case screening and surveillance.